Pharma Focus Asia

Resonant Therapeutics Announces Collaboration with Janssen

Wednesday, December 04, 2019

Resonant Therapeutics, Inc. announced that the company has entered into an agreement with Janssen Research and Development, LLC (“Janssen”) with the aim to discover and validate novel tumor and immunological targets, and to validate certain therapeutic candidates. The collaboration leverages Resonant’s proprietary IMPaCT tumor microenvironment model and target validation platform, which earned them a Johnson & Johnson Innovation - JLABS @ TMC QuickFire Challenge award in 2016, and Janssen industry-leading oncology capabilities to rapidly advance new targets and therapeutic opportunities.

ohn K. Westwick, Ph.D., Resonant Founder and CEO said “Resonant was launched to industrialize our tumor-microenvironment IMPaCT platform in order to efficiently discover, validate, and prioritize antibody therapeutics via a data-driven biological pipeline. We are delighted to collaborate with industry-leader Janssen with the aim to help validate therapeutic candidates and novel functional tumor and immunological targets for difficult-to-treat cancers.”

Specific details of the agreement were not disclosed.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024